Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Share-based Compensation (2021 - 2025)

Historic Share-based Compensation for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $7.1 million.

  • Amylyx Pharmaceuticals' Share-based Compensation rose 401.29% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year decrease of 2185.54%. This contributed to the annual value of $33.0 million for FY2024, which is 1109.5% down from last year.
  • As of Q3 2025, Amylyx Pharmaceuticals' Share-based Compensation stood at $7.1 million, which was up 401.29% from $7.4 million recorded in Q2 2025.
  • Amylyx Pharmaceuticals' 5-year Share-based Compensation high stood at $10.2 million for Q3 2023, and its period low was $586000.0 during Q1 2021.
  • For the 5-year period, Amylyx Pharmaceuticals' Share-based Compensation averaged around $6.1 million, with its median value being $6.8 million (2024).
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 76864.54% in 2022, then tumbled by 3314.66% in 2024.
  • Over the past 5 years, Amylyx Pharmaceuticals' Share-based Compensation (Quarter) stood at $1.1 million in 2021, then surged by 458.3% to $6.1 million in 2022, then soared by 56.53% to $9.5 million in 2023, then decreased by 29.3% to $6.7 million in 2024, then rose by 4.97% to $7.1 million in 2025.
  • Its last three reported values are $7.1 million in Q3 2025, $7.4 million for Q2 2025, and $6.8 million during Q1 2025.